內地吸入用新冠疫苗臨牀試驗結果獲認可 康希諾(06185.HK)飆逾一成
據內媒報道,由軍事科學院軍事醫學研究院陳薇團隊領銜研製的霧化吸入用腺病毒載體重組新冠疫苗,在國際學術期刊《柳葉刀傳染病》發表臨牀研究數據,這是全球首個公開發表的新冠疫苗黏膜免疫臨牀試驗結果。研究結果顯示,霧化吸入接種疫苗安全性好,無肌肉注射局部不良反應。
康希諾生物(06185.HK)有份合作研發霧化吸入式新冠疫苗,該股午後一度升近12%,最新仍升11.2%報289.8元,成交額約5.3億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.